Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the role of transmission of vagal cholinerg for the GLP-1 potentiation of the glucose stimulated insulin secretion and the cephalic insulin response by using atropin administration. The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the investigators will research individuals with an intact nervous supply with and without atropin administration.

Detailed Description
-----------------
GLP-1 is a importent enterogastron and incretin hormone. Rapid degradation of GLP-1 by dipeptidyl peptidase 4 (DPP-4) suggests that GLP-1 may act locally (through vagal afferents) before being degraded. We aimed to clarify the role of vagal innervation on the incretin effect.

Official Title
-----------------
The Significances of Atropin Administration for the GLP-1 Potentiation of Glucose Induced Insulin Secretion and the Cephalic Insulin Response

Conditions
-----------------
The Focus of This Study is to Evaluete the Significances of the Vagal Cholinerg Nervuos System for the Effect of GLP-1 by Using Atropin Administration.

Intervention / Treatment
-----------------
* Drug: Atropine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18 and 45 years normal fasting plasma glucose normal hemoglobin informed consent Exclusion Criteria: diabetes mellitus body mass index above 30 inflamatoric bowel disease intestinal surgery serum creatinine above 250 microM ALAT above to times normal value treatment with medicine wich cannot be paused for 12 hours contraindication for treatment with atropin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Atropin<br>Atropin | Drug: Atropine<br>* 1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.<br>|
| Placebo Comparator: Placebo<br>Saline | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin secretion | The insulin secretion during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration is evaluated. Also the insulin secretion during lightly elevated blood glucose during a sham-feeding with and without atropin administration is evaluated. | tree hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma PP | 20 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. | 20 time points within tree hours | 
| Plasma glucose | 30 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. | 30 within tree hours | 
| Plasma GLP-1 | 20 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. | 20 time points within tree hours | 
| Plasma GLP-1 | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 18 time points within tree hours | 
| Plasma GLP-2 | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 18 time points within tree hours | 
| Plasma GIP | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 18 timepoints within tree hours | 
| Plasma glucagon | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 18 timepoints within tree hours | 
| Plasma glucose | 33 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. | 33 timepoints within tree hours |